Ratings for DexCom (NASDAQ:DXCM) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ...
Dexcom provided a look at new data for the upcoming generation of its continuous glucose monitoring sensor. Presenting at the J.P. Morgan Healthcare Conference, the details were pulled from a large ...
Dexcom has rebounded since my last update, but I maintain a 'Hold' rating due to continued overvaluation and limited upside potential. Growth remains solid, especially in sensors and U.S. expansion, ...
Type 2 diabetes patients who take a GLP-1 such as Ozempic or Wegovy are associated with higher usage of continuous glucose monitors, Dexcom said Sept. 5, according to an Investor’s Business Daily ...
Diabetes tracker developer Dexcom is pushing back the timeline for a U.S. launch of the latest generation of its continuous glucose monitor, the G7, after the FDA raised questions about the device’s ...
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S.
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of updated t:slim X2™ insulin pump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback